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The potency of 5-fluoroorotate for inhibition of L929 or CVl-P cell growth is increased by encapsulation 
in negatively charged liposomes. The optimal liposome composition is dipalmitoylphosphatidylglycerol: 
cholesterol, 67:33. Unextruded large unilamellar liposomes are the optimal size for delivery. This compound 
is the second transport-negative drug which we have found to exhibit liposome-dependent delivery. 
Fluoropyrimidine Liposome Targeting 
1. INTRODUCTION 
We have previously used liposomes to increase 
the potency of drugs that are transported slowly in- 
to cells [ 11. 5Fluoroorotate is a derivative of 
5fluorouracil for which no cellular transport 
system exists [2]. 5Fluoroorotate is also a weak 
acid, and might enter the cytoplasm more readily 
by escape from the lysosomal compartment after 
delivery by liposomes [3,4]. Therefore, we have in- 
vestigated whether the potency of this drug is in- 
creased by encapsulation in negatively charged 
liposomes. 
2. MATERIALS AND METHODS 
Sodium 5fluoroorotate (Pharmacia, NJ) gave a 
maximum concentration of 15 mM, while the 
lithium salt was soluble to at least 50 mM. For en- 
capsulation, a 50 mM 5-fluoroorotate, pH 7.4, 
290 mosmol/kg solution was prepared, containing 
50 mM morpholinoethanesulfonate, 50 mM mor- 
pholinopropanesulfonate, chloride, and lithium as 
the counterion. For gel chromatography and 
subsequent dilution of the liposomes, an 
equivalent buffer lacking drug was prepared. All 
solutions were sterilised by filtration prior to use. 
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All phospholipids (Avanti, Birmingham, AL) 
were used without further purification. Choles- 
terol (Sigma, St Louis) was recrystallised 4 time; 
from methanol. All lipids were stored under argon 
in chloroform solution in sealed ampoules until 
use. Liposomes were prepared by reverse-phase 
evaporation [5], and extrusion [6]. Small lipo- 
somes were made by extensive sonication of lipid 
suspensions. The unencapsulated drug was re- 
moved by gel filtration with Sephadex G-75 (Phar- 
macia). Lipid concentration was measured by 
phosphorus analysis [7]. The encapsulated drug 
was measured using a molar extinction coefficient 
of 7100 in 0.1 N HCI. A liposome sample was ex- 
tracted [8], the upper phase was acidified with 
HCI, and its absorbance was measured. L929 [l] 
and CVl-P [9] cells were obtained and grown as 
previously described. The I& of the liposome 
preparations was measured by growth inhibition as 
in [l]. The cells were incubated for 48 h (L929) or 
72 h (CVl-P) before counting. 
3. RESULTS 
The captured aqueous volumes are within the ex- 
pected range for the liposome preparations [6]. 
This suggests that the drug is encapsulated within 
the aqueous phase, and does not leak very rapidly 
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Table 1 
Growth inhibition by 5fluoroorotate 
Lipidb Liposome properties lC:oa (~JM) 
Molar Size” Captured CVl-P L929 
ratio Ocm) (Wmol) 
Free drug’ - - _ 722 1.1 * 0.3 
PG : ChoI 67:33 U 9.0 2.0 0.6 
0.1 2.8 2.2 0.6 
DSPG : Chol 67:33 U 2.8 0.5 0.72 
suv 0.8 0.7 0.96 
DPPG : Chol 67:33 U 5.2 0.2 0.08 
0.1 3.2 0.2 0.13 
suv 1.2 1.7 0.8 
a Concentration of the drug that inhibits cell growth by 50% 
b Lipids used: Chol, cholesterol; PG, egg phosphatidylglycerol; DPPG, 
dipalmitoyiphosphatidyIgiycero1; DSPG, distearoylphosphatidyIglycero1 
’ Liposomes were prepared by reverse-phase vaporation, and were either 
unextruded (U), or extruded to 0.1 pm (0.1). Liposomes were also prepared 
by extensive sonication (SUV) 
d The theoretical aqueous capture is the drug:lipid ratio (mol/mol) x the 
inverse of the original drug concentration (0.05 M) 
’ The I&O of the free drug is the mean of 3 determinations for CV 1-P cells, and 
of 4 determinations forL929 cells. All other values are derived from individual 
growth inhibition curves 
from the liposomes. The liposomes may be stored 
for several weeks at 4°C without any change in 
their potency, which further confirms the stability 
of the preparations. 
Unencapsulated 5fluoroorotate has an ICXI of 
7 PM for CV-1P cells and 1 PM for L929 cells 
(table 1). When encapsulated in egg phosphatidyl- 
glycerol : cholesterol, 67 : 33 liposomes, the potency 
of 5fluoroorotate as increased 2-3-fold. How- 
ever, drug potency was increased 14-35fold by 
encapsulation in dipalmitoylphosphatidylgly- 
cerol : cholesterol, 67 : 33 liposomes. Sonicated 
liposomes of this composition were lo-fold less 
effective than larger liposomes for drug delivery. 
Drug in distearoylphosphatidylglycerol : choleste- 
rol, 67 : 33 unextruded liposomes was a 2-14-times 
more potent growth inhibitor than free drug. Soni- 
cated liposomes of this composition are less effec- 
tive than unextruded large liposomes, but the dif- 
ference is not as large as that between sonicated 
liposomes and unextruded liposomes that contain 
dipalmitoylphosphatidylglycerol. 
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4. DISCUSSION 
The liposome dependence of 5-fluoroorotate 
should assist considerably the study of targeted 
drug delivery. 5Fluoroorotate inhibits the con- 
tractility of fibroblasts, and may allow us to 
develop a specific therapy for intraocular pro- 
liferative diseases [lo]. 
S-Fluoroorotate may be considered a liposome- 
dependent derivative of 5-~uorouracil. Both drugs 
interfere with ribosomal maturation [ 11,121, and 
may also be metabolised to fluorodeoxyuridine 
monophosphate, an inhibitor of thymidylate syn- 
thetase [ 131. 5-Fluorouracil has a half-time of 
transmembrane flux of 30 s [14], while 5-fluoro- 
orotate exhibits very slow transmembrane flux [2]. 
5-Fluoroorotate may be more useful for use with 
liposomes than 5fluorouracil. Attempts to encap- 
sulate 5fluorouracil have met with limited success. 
5-Fluoroorotate appears to be stably incorporated 
into liposomes, presumably due to its negative 
charge. 
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Experiments on the use of liposomes for 
5fluoroorotate delivery have produced two unex- 
pected observations: (i) Liposomes containing 
dipalmitoyiphosphatidylglyceroi are more effec- 
tive for dehvery of 5-fluoroorotate than Iiposomes 
containing egg phosphatidylglycerol. (ii) Sonicated 
liposomes are much less effective than larger 
liposomes for 5fluoroorotate delivery, while 
previous studies have shown sonicated liposomes 
to be the most effective Iiposomes for dehvery of 
methotrexate or methotrexate-y-aspartate [ 15,161. 
These observations may be due to the rate of 
5fluoroorotate leakage from liposomes that are in 
contact with serum. In future studies, we hope to 
investigate the leakage of 5-fluoroorotate from 
liposomes, and its delivery by ligand-directed 
liposomes. 
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